The choice of treatment depends, among other parameters, on the presence of genetic alterations, such as mutations in the epidermal growth factor receptor (EGFR), a prognostic marker and predictive of response to TKIs, which varies among different series, approximately representing 15% of metastatic non-small cell lung cancers (mNSCLCs) [5]. Here, EGFR is linked to non-small cell lung carcinoma.